Cost of Hatch-Waxman Litigation Decreases (via tax deduction)
November 6, 2023, 9:53 AM
By: Aziz Burgy
As Benjamin Franklin famously remarked, “nothing is certain except death and taxes.” Recently, the U.S. Court of Appeals for the Third Circuit provided more certainty about the latter by holding that legal expenses incurred by generic drug manufacturers in defending patent infringement suits brought under the Hatch-Waxman Act are deductible from the manufacturers’ federal taxes as ordinary and necessary business expenses. Mylan, Inc. & Subsidiaries v. Comm'r of Internal Revenue, 76 F.4th 230 (3d Cir. 2023).
In the appeal, the Commissioner of Internal Revenue argued that these expenses should be capitalized, under 26 U.S.C. § 263 and the associated regulations, as amounts paid to acquire approvals from the Food and Drug Administration (“FDA”). Id. at 243. The Third Circuit rejected the Commissioner’s argument noting that “ultimate FDA approval is never decided by the outcome of patent litigation under [35 U.S.C.] § 271(e)(2), even if it is delayed by such litigation.” Id. at 244. The Third Circuit concluded that “it makes no difference in deciding the question of deductibility whether the patent litigation expenses are incurred by the patentee or the alleged infringer. Nor does it matter that the deductibility question arises in the context of an ANDA suit.” Id. at 239-240.
Generic drug manufacturers can certainly leverage this ruling at corporate tax time. Companies should also consult with their tax advisors about the treatment of costs associated with the preparation, assembly, and transmittal of notice letters required by the Abbreviated New Drug Application.

To subscribe to our publications, click here.
Tags
News & Insights
News & Insights
ACI Forum on Pharma & Biotech Patent Litigation USA 2025
Speaking Engagement
Intellectual Property
CCWC 21st Annual Career Strategies Conference
Speaking Engagement
Fordham 52nd Annual Conference on International Antitrust Law and Policy
Speaking Engagement
Antitrust
Kisaco Research Trade Secret Legal Protection Conference 2025
Speaking Engagement
Intellectual Property
SCCE 23rd Annual Compliance & Ethics Institute
Speaking Engagement
Antitrust
29th Annual IBA Competition Conference
Sponsorship
Antitrust
Key Appellate Decisions Shaping Antitrust Strategy
Webinar
Antitrust
New Frontiers of Antitrust – 16th Annual International Conference of Concurrences Review
Speaking Engagement
Antitrust
MCCA Pathways Conference
Sponsorship
Antitrust
HNBA/VIA Annual Convention 2025
Sponsorship
Antitrust